Whipplewood Advisors LLC Takes $37,000 Position in argenx SE (NASDAQ:ARGX)

Whipplewood Advisors LLC acquired a new position in shares of argenx SE (NASDAQ:ARGX) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 60 shares of the company’s stock, valued at approximately $37,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Global Retirement Partners LLC raised its stake in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after acquiring an additional 48 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of argenx in the fourth quarter valued at $66,000. Nkcfo LLC purchased a new stake in shares of argenx in the 4th quarter valued at $68,000. Advisors Preferred LLC acquired a new position in argenx during the 4th quarter worth about $73,000. Finally, Financial Perspectives Inc boosted its holdings in argenx by 39.4% during the 4th quarter. Financial Perspectives Inc now owns 145 shares of the company’s stock valued at $89,000 after acquiring an additional 41 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ARGX has been the topic of a number of recent research reports. Wells Fargo & Company boosted their price target on shares of argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research note on Friday. HC Wainwright upped their target price on shares of argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research note on Friday. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target for the company in a research report on Tuesday, November 12th. Evercore ISI upped their price objective on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, JMP Securities lifted their target price on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $661.17.

argenx Price Performance

Shares of ARGX opened at $624.67 on Friday. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21. The stock has a market cap of $37.96 billion, a PE ratio of -709.85 and a beta of 0.58. The firm has a fifty day moving average price of $642.62 and a 200 day moving average price of $590.74.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.